

## Special Issue

# COVID-19, Neuroinflammation and Therapeutics, 2nd Edition

### Message from the Guest Editor

With a continuously growing knowledge base due to information gathered from epidemiological studies, randomized controlled trials (RCTs), observational studies, case reports, and meta-analytical reviews, new light has been shed on different aspects of the direct and indirect disease burden associated with COVID-19. Although primarily a disease of the respiratory system, systematic inflammatory and immune responses have also emerged as a result of COVID-19; this indicates that its manifestations are diverse and affect multiple systems, including the nervous system. This Special Issue aims to fill knowledge gaps on COVID-19. We are inviting research papers, including reports, observational studies, RCTs, reviews (including narrative reviews), and meta-analytical reviews, that provide novel insights into the clinical features, treatments, therapeutics, and inflammatory biomarkers of COVID-19 (e.g., through laboratory-, neuroimaging-, or neurophysiology-based approaches). Bringing this new research to the forefront of the scientific community will enhance our understanding of this virus and its effects, especially those related to its neurological complications.

---

### Guest Editor

Dr. Yasir Rehman

Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada

---

### Deadline for manuscript submissions

closed (31 October 2024)



## Neurology International

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.2  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/si/188905](https://mdpi.com/si/188905)

*Neurology International*  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[neurolint@mdpi.com](mailto:neurolint@mdpi.com)

[mdpi.com/journal/  
neurolint](https://mdpi.com/journal/neurolint)





# Neurology International

an Open Access Journal  
by MDPI

Impact Factor 3.2  
CiteScore 3.7  
Indexed in PubMed



[mdpi.com/journal/  
neurolint](https://mdpi.com/journal/neurolint)



## About the Journal

### Message from the Editor-in-Chief

---

#### Editor-in-Chief

Prof. Dr. Junji Yamauchi

1. Laboratory of Molecular Neurology, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan
  2. Department of Pharmacology, National Research Institute for Child Health and Development, Setagaya, Tokyo 157-8535, Japan
- 

#### Author Benefits

##### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

##### High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, and other databases.

##### Journal Rank:

JCR - Q2 (Clinical Neurology)